{
  "url": "https://openlegislation.uk/eu-regulation-2014-406/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2014-406/annex.json",
  "legislation": "eur/2014/406",
  "legislation_title": "Commission Implementing Regulation (EU) No 406/2014 of 23 April 2014 to approve ethyl butylacetylaminopropionate as an existing active substance for use in biocidal products for product-type 19 (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2014-406",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 8 of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.\nFor the implementation of the common principles of Annex VI to Regulation (EU) No 528/2012, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm\nCommon Name\nIUPAC NameIdentification Numbers\nMinimum degree of purity of the active substance\nDate of approval\nExpiry date of approval\nProduct type\nSpecific conditions\nEthyl butylacetylaminopropionate\nIUPAC Name:\n3-(N-acetyl-N-butyl)aminopropionic acid ethyl ester\nEC no: 257-835-0\nCAS no: 52304-36-6\n990 g/kg\n1 November 2015\n31 October 2025\n19\nThe product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.\nAuthorisations are subject to the following condition:\nPrimary exposure of humans to the product shall be minimized by considering and applying appropriate risk mitigation measures, including, where applicable, instructions on the amount and the frequency with which the product may be applied to human skin.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 8 of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance."
    },
    {
      "type": "footnote",
      "label": "f2",
      "text": "For the implementation of the common principles of Annex VI to Regulation (EU) No 528/2012, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2014/406/annex",
    "retrieved_at": "2026-11-01T14:47:44.138260+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}